

図1 インターフェロン抵抗性試験とペグインターフェロン・リバビリン併用療法

結果

全107例中29例(27.1%)で治療中ペグインターフェロンを、49例(45.8%)でリバビリンを減量したが中止例はなかった。治療中の血中HCV RNAの陰性化はRVRが6例(5.6%), EVR40例(37.4%)、投与終了時の血中HCV RNA陰性化例77例(72.0%)であり、最終的な治療効果としてはSVR39例(36.5%)、再燃(relapse)例38例(35.5%)、NR30例(28.0%)であった。

HCVの各領域のアミノ酸変異の検討では、Core領域70番のアミノ酸はarginine(Arg)70例(65.4%)・glutamine(Gln)29例(27.1%)であり、残り8例中5例はhistidine、3例はArgとGlnのmixed typeであった。Core領域91番のアミノ酸ではleucine(Leu)76例(71.0%)、methionine(Met)29例(27.1%)であり、残りの2例はLeuとMetのmixed typeであった。E1領域の139番のアミノ酸ではthreonine(Thr)55例(51.4%)、alanine(Ala)40例(37.4%)であり、残り12例中serineが2例、ThrとAlaのmixed typeが4例、deletionが4例あり、ほかの2例では領域が増幅できなかった。一方、NS5A領域のISDRの変異については、HCV-Jとの比較で変異数が2以下のものをwild type、3以上のものをnon-wild typeとすると、wild type64例(59.8%)、non-wild type43例(40.2%)であった。なお、いずれの変異も年齢・性・肝線維化の程度と関連を認めなかった。

各領域のアミノ酸による投与前開始前のウイルス量の比較を図2に示す。インターフェロン抵抗性とされているNS5A領域のISDRのwild typeでnon-wild typeに比べ有意に高く(2076 ± 1213 KIU/ml vs. 1291 ± 830 KIU/ml; $P=0.0004$)、今までの報告と一致した。一方、Core領域70番のアミノ酸での比較ではインターフェロン抵抗性とされているCore 70-Gln症例でArgに比べ投与前開始前のウイルス量はむしろ低かった(1410 ± 895 KIU/ml vs. 1943 ± 1204 KIU/ml; $P=0.0260$)。Core領域91番とE1領域139番のアミノ酸については投与前開始前のウイルス量に差はみられなかった。

次にインターフェロン感受性試験後のウイルス量の低下をみると(図3)、通常のインターフェロンα投与24時間後の血中HCV RNA量はCore領域70番のアミノ酸がArgの症例でGlnの症例に比べ有意に低下した($1.50 \pm 0.45 \log_{10}$ vs. $0.95 \pm 0.69 \log_{10}$, $P<0.0001$)。また、ペグインターフェロン・リバビリン併用療法開始後24時間の時点でも血中HCV RNA量はCore領域70番のアミノ酸がArgの症例でGlnの症例に比べ有意に低下した($1.36 \pm 0.52 \log_{10}$ vs. $0.97 \pm 0.57 \log_{10}$, $P=0.0025$; 図4)。一方、Core領域91番・E1領域139番・NS5A領域ISDRのアミノ酸とインターフェロン感受性試験後のウイルス量の低下、ペグインターフェロン・リバビリン併用療法開始後24時間の時点でのウイルス量の低下との間には関連は認められなかった。

各領域のアミノ酸変異によるRVR・EVRおよび




図2 HCV Core・E1・NS5A領域のアミノ酸変異と治療前のHCV RNA量 (amplicor monitor 法・version 2.0 : KIU/ml)




図3 HCV Core・E1・NS5A領域のアミノ酸変異とインターフェロン抵抗性試験によるHCV RNAの低下 (log₁₀)




図4 HCV Core・E1・NS5A領域のアミノ酸変異とペグインターフェロン・リバビリン併用療法開始24時間後のHCV RNAの低下(log₁₀)




図5 HCV Core・E1・NS5A領域のアミノ酸変異とrapid virologic response

最終的な治療効果を図5~7に示す。RVR症例は6例のみであったがISDRのnon-wild typeにおいて

wild typeより有意に多いという結果が得られた(P=0.0045)。EVRについてはCore領域70番のアミノ




図6 HCV Core・E1・NS5A領域のアミノ酸変異と early virologic response




図7 HCV Core・E1・NS5A領域のアミノ酸変異と treatment outcome

酸により有意差をもってEVR率に差がみられ($P < 0.0001$)。同部位のアミノ酸がArgの症例では50%以上がEVRになったのに対し、Glnの症例でEVRになったのはわずか1例であった。最終的な治

療効果においてもCore領域70番のアミノ酸は治療効果に強く影響しており($P < 0.0001$)。同部位のアミノ酸がArgの症例では50%近くの症例がSVRとなり、対照的にGlnの症例では50%以上がNRで

表 3 Early virologic responseに関する因子(多変量解析)

| Factor | | parameter estimate | standard error | X | Odds ratio (95% confidence interval) | P value |
|----------------|-------------|--------------------|----------------|-------|--------------------------------------|---------|
| ・年齢 | 1: ≤60歳 | | | | 1 | |
| | 2: >60歳 | 0.4870 | 0.3236 | 2.27 | 2.6487(0.7693~10.048) | 0.1323 |
| ・性別 | 1: 男性 | | | | 1 | |
| | 2: 女性 | -0.4370 | 0.4363 | 1.00 | 0.4173(0.0651~2.1643) | 0.3165 |
| ・体重 | 1: ≤60kg | | | | 1 | |
| | 2: >60kg | -0.6198 | 0.4282 | 2.09 | 0.2895(0.0459~1.4281) | 0.1478 |
| ・肝組織像-activity | 1: A0/A1 | | | | 1 | |
| | 2: A2/A3 | -0.0797 | 0.4175 | 0.04 | 0.8527(0.1614~4.5255) | 0.8487 |
| ・肝組織像-fibrosis | 1: F0/F1 | | | | 1 | |
| | 2: F2/F3 | 0.0177 | 0.4419 | 0.00 | 1.0360(0.1791~6.0891) | 0.9681 |
| ・Core-70 | 1: Arg | | | | 1 | |
| | 2: Gln | -1.9777 | 0.5990 | 10.90 | 0.0191(0.0008~0.1314) | 0.0010 |
| ・Core-91 | 1: Leu | | | | 1 | |
| | 2: Met | -0.1308 | 0.4518 | 0.08 | 0.7699(0.1239~4.6302) | 0.7722 |
| ・E1-139 | 1: Thr | | | | 1 | |
| | 2: Ala | -0.3073 | 0.3290 | 0.87 | 0.5408(0.1442~1.9603) | 0.3503 |
| ・NS5A-ISDR | 1: wild | | | | 1 | |
| | 2: non-wild | 0.4002 | 0.3336 | 1.44 | 2.2266(0.6143~8.6856) | 0.2303 |

表 4 Sustained virologic responseに関する因子(多変量解析)

| Factor | | Parameter estimate | Standard error | X | Odds ratio (95% confidence interval) | P value |
|----------------|-------------|--------------------|----------------|------|--------------------------------------|---------|
| ・年齢 | 1: ≤60歳 | | | | 1 | |
| | 2: >60歳 | 0.2172 | 0.3114 | 0.49 | 1.5441(0.4544~5.3670) | 0.4854 |
| ・性別 | 1: 男性 | | | | 1 | |
| | 2: 女性 | -0.6361 | 0.4263 | 2.23 | 0.2802(0.0443~1.3663) | 0.1356 |
| ・体重 | 1: ≤60kg | | | | 1 | |
| | 2: >60kg | -0.5240 | 0.4129 | 1.61 | 0.3507(0.0593~1.6447) | 0.2045 |
| ・肝組織像-activity | 1: A0/A1 | | | | 1 | |
| | 2: A2/A3 | 0.2470 | 0.4220 | 0.34 | 1.6388(0.3167~9.2242) | 0.5584 |
| ・肝組織像-fibrosis | 1: F0/F1 | | | | 1 | |
| | 2: F2/F3 | -0.4120 | 0.4451 | 0.86 | 0.4387(0.0702~2.4515) | 0.3546 |
| ・Core-70 | 1: Arg | | | | 1 | |
| | 2: Gln | -1.6373 | 0.5636 | 8.44 | 0.0378(0.0019~0.2322) | 0.0037 |
| ・Core-91 | 1: Leu | | | | 1 | |
| | 2: Met | -0.2967 | 0.4388 | 0.46 | 0.5524(0.0870~2.9801) | 0.4989 |
| ・E1-139 | 1: Thr | | | | 1 | |
| | 2: Ala | -0.3015 | 0.3262 | 0.85 | 0.5471(0.1481~1.9691) | 0.3553 |
| ・NS5A-ISDR | 1: wild | | | | 1 | |
| | 2: non-wild | 0.4233 | 0.3294 | 1.65 | 2.3317(0.6553~8.9412) | 0.1988 |

あった。EVRおよび最終的な治療効果においてCore領域91番・E1領域139番・NS5A領域ISDRのアミノ酸による比較では有意な差は認められなかった。

EVR・SVR・NRに対して年齢・性・体重・組織像(activityおよびfibrosis)と各領域のアミノ酸変異を因子として多変量解析を行うと、EVR・SVR・NRいずれの場合においてもCore領域70番のアミノ酸変異のみが独立して有意に関与する因

子であった(表3~5)。

考 察

NS5A-ISDRのアミノ酸配列とインターフェロン単独療法の効果との関係が報告されて以来、HCVの各領域のアミノ酸配列とインターフェロンを中心とした抗HCV療法との関連を検討した報告が多くみられるが、今回の検討では最近報

表5 Null-responseに関与する因子(多変量解析)

| Factor | Parameter estimate | Parameter estimate | Standard error | X | Odds ratio (95% confidence interval) | P value |
|--------------------|--------------------|--------------------|----------------|------|--------------------------------------|---------|
| ・年齢 | 1: ≤60歳 | | | | 1 | |
| | 2: >60歳 | 0.0351 | 0.3118 | 0.01 | 1.0727(0.3058~3.6504) | 0.9104 |
| ・性別 | 1: 男性 | | | | 1 | |
| | 2: 女性 | 0.1000 | 0.4186 | 0.06 | 1.2214(0.2408~6.8212) | 0.8112 |
| ・体重 | 1: ≤60kg | | | | 1 | |
| | 2: >60kg | 0.1958 | 0.3919 | 0.25 | 1.4795(0.3210~7.2819) | 0.6173 |
| ・肝組織像 -activity | 1: A0/A1 | | | | 1 | |
| | 2: A2/A3 | -0.0167 | 0.4121 | 0.00 | 0.9672(0.1748~4.7639) | 0.9678 |
| ・肝組織像 -fibrosis | 1: F0/F1 | | | | 1 | |
| | 2: F2/F3 | -0.0421 | 0.4253 | 0.01 | 0.9193(0.1665~4.9935) | 0.9212 |
| ・Core-70 | 1: Arg | | | | 1 | |
| | 2: Gln | 0.9716 | 0.3214 | 9.14 | 6.9812(2.0852~26.906) | 0.0025 |
| ・Core-91 | 1: Leu | | | | 1 | |
| | 2: Met | 0.3489 | 0.4105 | 0.72 | 2.0091(0.3841~10.144) | 0.3954 |
| ・E1-139 | 1: Thr | | | | 1 | |
| | 2: Ala | 0.5052 | 0.3400 | 2.21 | 2.7469(0.7453~11.201) | 0.1373 |
| ・NS5A-ISDR | 1: wild | | | | 1 | |
| | 2: non-wild | -0.0605 | 0.3304 | 0.03 | 0.8860(0.2339~3.2396) | 0.8547 |

告されたCore領域70番のアミノ酸変異がHCVのインターフェロンへの感受性、およびペグインターフェロン・リバビリン併用療法への反応と治療効果に大きく関与していることが示された。Core領域70番のアミノ酸がGlnの症例ではArgの症例に比べてインターフェロン感受性試験における血中のHCV RNAの低下率は有意に低く、インターフェロンに対する抵抗性を示唆した。われわれの検討ではインターフェロン単回投与24時間後、もしくはペグインターフェロン・リバビリン併用療法開始24時間後のウイルス量の低下の悪さはペグインターフェロン・リバビリン併用療法におけるNRと強く関連しており²⁰⁾、したがってCore領域70番のアミノ酸変異はペグインターフェロン・リバビリン併用療法に対するNRとの強い関連が考えられていたが、今回の検討ではSVRに対してもきわめて強い関連がみられた。芥田らの報告ではCore領域のアミノ変異は70番と91番がともにmutant(GlnとMet)であるいわゆるdouble mutant症例がペグインターフェロン・リバビリン併用療法に対し強い抵抗性を示すとされるが、Core領域70番のアミノ酸変異は単独でも現行のペグインターフェロン・リバビリン併用療法の効果に対して強く影響しているようである。

一方、NS5A領域のISDRの変異はペグインターフェロン・リバビリン併用療法におけるRVRとの関連が示唆された。RVR症例は最終的なSVRを予測するもっとも強い因子とされる^{21,22)}。今回の検討ではISDRの変異のSVRへの関与は認められなかったが、今回の検討は症例がgenotype 1Bの高ウイルス量症例に限られており、低ウイルス量症例も含めてHCV genotype 1B全体の検討ではISDRの変異がSVRに関与する可能性がある。また、ISDRの変異に関しては、従来の報告通り投与前のHCV RNA量との関連が示された。インターフェロンを用いた抗HCV療法においてはgenotypeがもっとも強く治療効果に関与するが、同一のgenotypeの場合には治療前のHCV RNA量は重要な効果規定因子である。さらに最近のreal-time PCR法を用いたHCV RNA定量の導入によりその重要性は増している。今回の検討ではHCV RNA量の評価はamplicor monitor法によっているが、real-time PCRでのHCV RNA量の評価によりペグインターフェロン・リバビリン併用療法におけるISDR変異の位置づけも変わるかもしれない。

おわりに

今回、HCV genotype 1Bの高ウイルス量症例に限りHCVの4か所のアミノ酸変異とインター

フェロンへの感受性、ペグインターフェロン・リバビリン併用療法の効果との関連を検討した。今回の検討ではCore領域70番のアミノ酸変異がきわめて強く治療効果と関連していた。しかしそのメカニズムは不明であり、今後の研究が待たれる。またgenotype 1B, および他のgenotypeにおいても上記以外のHCVのさまざまな領域のアミノ酸変異とインターフェロン療法の効果との関連が現在も研究されており、われわれは今後もこれらの研究結果を慎重に見極めていく必要がある。

文 献

- 1) Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001 ; 358 : 958-65.
- 2) Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002 ; 345 : 975-82.
- 3) Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology* 2003 ; 38 : 645-52.
- 4) Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon- α 2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 2004 ; 140 : 346-55.
- 5) Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. *Gastroenterology* 2004 ; 126 : 1015-23.
- 6) Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. *Gastroenterology* 2004 ; 127 : 1724-32.
- 7) Dalgard O, Bjørn K, Hellum KB, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. *Hepatology* 2004 ; 40 : 1260-5.
- 8) Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients with HCV genotypes 2 or 3. *J Hepatol* 2004 ; 40 : 993-9.
- 9) Bruno S, Camma C, Di Marco V, et al. Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. *J Hepatol* 2004 ; 41 : 474-81.
- 10) Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. *N Engl J Med* 2005 ; 352 : 2609-17.
- 11) von Wagner M, Huber M, Berg T, et al. Peginterferon- α -2a (40kD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. *Gastroenterology* 2005 ; 129 : 522-7.
- 12) Brandao C, Barone A, Carrilho F, et al. The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon α -2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1. *J Viral Hepat* 2006 ; 13 : 552-9.
- 13) Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N Engl J Med* 1996 ; 334 : 77-81.
- 14) Yang SS, Lai MY, Chen DS, et al. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. *Liver Int* 2003 ; 23 : 426-33.
- 15) Watanabe H, Nagayama K, Enomoto N, et al. Amino acid substitutions in PKR-eIF2 phosphorylation homology domain (PePHD) of hepatitis C virus E2 protein in genotype 2a/2b and 1b in Japan and interferon efficacy. *Hepatol Res* 2003 ; 26 : 268-74.
- 16) Sugihara K, Orito E, Tanaka Y, et al. Variation in the viral NS5B region in Japanese patients with chronic hepatitis C virus genotype 1 infection. No specific amino acid substitution was identified as determinants of treatment response to interferon/ribavirin combination therapy. *Intervirology* 2006 ; 49 : 319-26.

and A3 in four, and the fibrosis grade was F0 in three patients, F1 in 39, F2 in 11 and F3 in four. Liver biopsy was not performed for four patients.

Study design

All patients were given peginterferon α -2b (Schering-Plough, Osaka, Japan) weekly and ribavirin (Schering-Plough) daily. For peginterferon, patients weighing ≤ 45 kg were given 60 μ g, those > 45 kg and ≤ 60 kg were given 80 μ g, those > 60 kg and ≤ 75 kg were given 100 μ g, those > 75 kg and ≤ 90 kg were given 120 μ g and those > 90 kg were given 150 μ g according to the manufacturer's recommendations. The ribavirin dosage was also adjusted according to body weight. Patients ≤ 60 kg were given 600 mg, those > 60 kg and ≤ 80 kg were given 800 mg and those > 80 kg were given 1000 mg according to the manufacturer's recommendations.

Serum HCV RNA was measured 4 weeks after the start of therapy. Patients with detectable serum HCV RNA underwent the standard 24-week treatment. Patients with no detectable serum HCV RNA were randomly assigned to one of two groups; one group underwent the 8-week treatment, and the other underwent the standard 24-week treatment. When relapse occurred after completion of treatment in the 8-week group, it was recommended that the patients undergo retreatment with the same dose of peginterferon α -2b and ribavirin for an additional standard 24 weeks.

All patients were monitored during the treatment period and for an additional 6 months after the end of treatment. They underwent weekly outpatient evaluations during the first 2 months and monthly evaluations during the rest of the treatment period and during the 6-month follow-up period. Patients underwent a physical examination, complete blood

count, laboratory tests and serum HCV RNA measurement. Serum HCV RNA was measured using a COBAS TaqMan HCV test (Roche Molecular Systems); the detection limit was 15 copies/ml. SVR was defined as a continuous absence of serum HCV RNA up to 6 months after the completion of therapy.

Statistical analysis

Quantitative values are shown as mean \pm standard deviation. Between-group differences were analysed using the χ^2 test. Differences in quantitative values between two groups were analysed using the Mann-Whitney *U*-test. All *P* values were two tailed, and *P* < 0.05 was accepted as being statistically significant.

The study protocol was approved by the hospital ethics committee and was carried out in compliance with the Helsinki declaration. Written informed consent was obtained from each patient before enrolment in this study.

Results

One patient dropped out of this study within 4 weeks after the start of treatment because of severe general malaise (Fig. 1). Therefore, serum HCV RNA at 4 weeks after the start of therapy was measured in 60 patients. Serum HCV RNA was detected in 28 (46.7%) patients and was not detected in 32 (53.3%) patients (RVR). The characteristics of RVR and non-RVR patients are listed in Table 2. A history of transfusion was most prevalent and the HCV RNA concentration was the lowest in RVR patients. The 32 RVR patients were randomized at 4 weeks after the start of therapy: 8-week group (*n* = 15) and 24-week group (*n* = 17, Fig. 1). Patients in the 8-week group underwent an additional 4 weeks of treatment. Patients in the 24-week group underwent an additional 20 weeks of treatment. No difference was found in the background characteristics between these two groups. The single dose of peginterferon and ribavirin was reduced in one and five of 17 patients, respectively, in the 24-week group, whereas no patient required reduction of the dose of peginterferon or ribavirin in the 8-week group. In non-RVR patients, three of 28 patients required reduction of the peginterferon dose, and six of 28 patients required reduction of the ribavirin dose during the treatment period. No patient required discontinuation of peginterferon or ribavirin during the treatment regimen and no patient dropped out of this study during the treatment or follow-up periods.

In patients who achieved an RVR, the SVR rate was 82.4% (14 of 17 patients) in the 24-week group and 33.3% (five of 15 patients) in the 8-week group. The SVR rate was significantly lower in the 8-week group than that in the 24-week group (*P* = 0.0140). Nine of 10 patients with relapse after treatment in the 8-week group subsequently underwent retreatment with the standard 24-week regimen (one patient declined retreatment). The SVR rate in this retreatment group was 77.8% (seven of nine patients). The SVR rate of the entire 8-week group, when including seven SVR patients by retreatment, was 80.0% (12 of 15 patients). The SVR rate between the 8- and the 24-week groups was similar when patients with an SVR by retreatment were included in the 8-week group (*P* = 0.8650). The SVR rate of patients without an RVR (non-RVR) was 53.6% (15 of 28 patients), which was between that of the 24-week group with an RVR and that of the 8-week group.

The characteristics and outcomes of patients in the 8-week group are listed in Table 3. There was no difference in patient

Table 1. Clinical characteristics of the study patients (*n* = 61)

| | |
|---|-------------------------------------|
| Age (years) | 56.7 \pm 11.2 |
| Gender (female/male) | 37 (60.7)/24 (39.3) |
| History of interferon therapy (naïve/retreatment) | 40 (65.6)/21 (34.4) |
| History of transfusion (no/yes) | 44 (72.1)/17 (27.9) |
| Alanine aminotransferase (IU/L) | 51.4 \pm 56.4 |
| Aspartate aminotransferase (IU/L) | 45.7 \pm 49.2 |
| γ -glutamyl transpeptidase (IU/L) | 58.7 \pm 123.7 |
| Alkaline phosphatase (IU/L) | 270.5 \pm 147.9 |
| Albumin (g/dl) | 4.30 \pm 0.33 |
| Total bilirubin (mg/dl) | 0.65 \pm 0.24 |
| White blood cell count (/ μ l) | 5001 \pm 1602 |
| Haemoglobin (g/dl) | 14.0 \pm 1.5 |
| Platelet count ($\times 10^3$ / μ l) | 19.5 \pm 6.5 |
| Body weight (kg) | 59.1 \pm 10.9 |
| Liver histology – activity (A0/A1/A2/A3)* | 1 (1.8)/39 (68.4)/13 (22.8)/4 (7.0) |
| Liver histology – fibrosis (F0/F1/F2/F3)* | 3 (5.3)/39 (68.4)/11 (19.3)/4 (7.0) |
| HCV genotype (2a/2b) | 46 (75.4)/15 (24.6) |
| HCV RNA concentration ($\times 10^3$ IU/ml) | 1919 \pm 1618 |

Percentages are shown in parentheses.

*Liver biopsy was not performed in four patients.

HCV, hepatitis C virus.




Fig. 1. Schematic of the trial profile. Serum hepatitis C virus (HCV) RNA was negative in 32 patients (rapid virological responders), and they were assigned to the 8-week regimen (15 patients) or the standard 24-week regimen (17 patients). Nine of 10 relapsers in the 8-week group underwent retreatment with the standard 24-week regimen. SVR, sustained virological response; RVR, rapid virological response.

age, gender, liver histology, HCV genotype, pretreatment HCV RNA concentration or detection of serum HCV RNA at 2 weeks after the start of therapy between patients with an SVR and those who relapsed. Serum HCV RNA was detected at 4 weeks after the end of therapy in all patients with relapse, with the exception of one patient with serum HCV RNA detected at 8 weeks after the end of therapy. Nine of 10 relapsers underwent retreatment within 1–6 months after the end of the initial treatment. The HCV RNA concentration just before retreatment was higher than that before the initial treatment in four patients, and was lower than that before the initial treatment in five patients. Two patients relapsed after retreatment, and the other seven patients achieved an SVR. One patient required reduction of the peginterferon dose, and two patients required reduction of the ribavirin dose during retreatment. No patient required discontinuation of peginterferon or ribavirin during either the initial treatment or the retreatment period.

Discussion

Shortening the period of antiviral therapy with peginterferon and ribavirin is important in terms of adverse effects and

medical costs. A shortened regimen may be less expensive and better tolerated by the majority of patients. Studies on shorter treatment performed so far are different in terms of the design, the characteristics of the population and the virological methods used; these differences may account for the different relapse rates reported so far after an abbreviated course (7–9). Moreover, the possibility to further reduce to an 8-week treatment duration had not been investigated so far.

In the present study, we evaluated an 8-week regimen for patients with HCV genotype 2 and RVR. It has been reported recently that antiviral therapy is more beneficial for patients with HCV genotype 2 than for those with HCV genotype 3 (4, 6). In addition, achievement of an RVR is a reported indicator of the highest likelihood of SVR in response to short-duration therapy. Patients who were assigned to the 8-week regimen were, therefore, the population with the highest likelihood of achieving an SVR.

The results of the present study clearly showed that reduction of the treatment duration to 8 weeks is not sufficient as an antiviral therapy for patients with chronic infection of HCV genotype 2 (2a or 2b), at least in patients with pretreatment HCV RNA concentrations $> 100 \times 10^3$ IU/ml, even though an RVR is achieved. A marked increase in the rate of relapse after the completion of treatment was observed in patients in the

Table 2. Characteristics of rapid virological responders and non-rapid virological responders*

| | Rapid virological responders (n = 32) | Non-rapid virological responders (n = 28) | P value |
|---|---------------------------------------|---|---------|
| Gender (years) | 55.6 ± 12.7 | 57.8 ± 9.6 | 0.7553 |
| Sex (female/male) | 20 (62.5)/12 (37.5) | 16 (57.1)/12 (42.9) | 0.8741 |
| History of interferon therapy (naïve/retreatment) | 19 (59.4)/13 (40.6) | 21 (75.0)/7 (25.0) | 0.3142 |
| History of transfusion (no/yes) | 2 (6.3)/30 (93.7) | 16 (57.1)/12 (42.9) | 0.0004 |
| Alanine aminotransferase (IU/L) | 49.3 ± 57.7 | 54.4 ± 56.8 | 0.9409 |
| Aspartate aminotransferase (IU/L) | 46.3 ± 54.8 | 45.6 ± 43.9 | 0.2354 |
| γ-glutamyl transpeptidase (IU) | 64.3 ± 149.4 | 53.7 ± 90.7 | 0.6037 |
| Alkaline phosphatase (IU/L) | 244.7 ± 99.6 | 302.0 ± 187.8 | 0.1848 |
| Albumin (g/dl) | 4.35 ± 0.26 | 4.25 ± 0.41 | 0.2368 |
| Total bilirubin (mg/dl) | 0.67 ± 0.25 | 0.63 ± 0.23 | 0.7411 |
| White blood cell count (/μl) | 4961 ± 1269 | 5052 ± 1963 | 0.9882 |
| Haemoglobin (g/dl) | 13.9 ± 1.3 | 14.1 ± 1.7 | 0.6944 |
| Platelet count (× 10 ³ /μl) | 19.0 ± 7.1 | 20.0 ± 6.0 | 0.3660 |
| Body weight (kg) | 56.6 ± 9.2 | 62.2 ± 12.1 | 0.1044 |
| Liver histology – activity (A0/A1/A2/A3)† | 1 (3.3)/22 (73.4)/6 (20.0)/1 (3.3) | 0/17 (65.4)/6 (23.1)/3 (11.5) | 0.4997 |
| Liver histology – fibrosis (F0/F1/F2/F3)† | 2 (6.6)/22 (73.3)/5 (16.7)/1 (3.3) | 1 (3.9)/16 (61.5)/6 (23.1)/3 (11.5) | 0.5526 |
| HCV genotype (2a/2b) | 27 (84.4)/5 (15.6) | 18 (64.3)/10 (35.7) | 0.1352 |
| HCV RNA concentration (× 10 ³ IU/ml) | 1197 ± 979 | 2713 ± 1848 | 0.0002 |
| Treatment duration (8 weeks/24 weeks) | 15/17 | 0/28 | |

Percentages are shown in parentheses.

*Rapid virological responders, serum HCV RNA was negative at 4 weeks after the start of therapy; non-rapid virological responders, serum HCV RNA remained positive at 4 weeks after the start of therapy.

†Liver biopsy was not performed in four patients.

HCV, hepatitis C virus.

8-week group compared with reported rates with treatment periods of 12–16 weeks (5, 6, 8); the relapse rate in RVR patients was 0% in those on a 16-week regimen (8), 9.5% in those on a 14-week regimen (5), 9.2% in those on a 12-week regimen (6) and 66.7% in those on the 8-week regimen in the present study. (The study of the 14-week regimen involved patients with undetectable HCV RNA at 8 weeks after the start of therapy in addition to RVR patients.) This marked increase in the relapse rate in the 8-week group strongly indicates the limitations of shortening the treatment period in patients with HCV genotype 2, even when an RVR is achieved. Although the appropriate duration of combination therapy for patients with HCV genotype 2 remains controversial (5–9), shortening the treatment period to 8 weeks is definitely insufficient as an antiviral therapy.

The very low SVR rate in the 8-week group could be accounted for, in part, by the higher pretreatment HCV RNA concentration. Our study did not include patients with a pretreatment HCV RNA concentration $\leq 100 \times 10^3$ IU/ml because only peginterferon monotherapy is allowed by Japanese National Medical Insurance for this patient population. SVR rates reportedly decrease in inverse proportion to pretreatment HCV RNA concentrations (2, 3, 12), and patients with a low pretreatment HCV RNA concentration, as well as those with RVR, reportedly have the highest likelihood of an SVR in response to short-duration therapy (9). Evaluation of the 8-week regimen in patients with HCV genotype 2 and with a

low pretreatment HCV RNA concentration ($\leq 100 \times 10^3$ IU/ml) is necessary. Another reason for the very low SVR rate in the 8-week group could be the slightly lower dose of ribavirin used, in comparison with that in previous reports. The dosage of ribavirin was decided according to the manufacturer's recommendations for Japanese patients, which was slightly lower than that for patients in Western countries. The increase in the ribavirin dose, therefore, might have increased the SVR rate in this patient population.

In summary, an 8-week regimen of antiviral combination therapy with peginterferon and ribavirin yielded a very high relapse rate, indicating the limitation of shortened treatment in patients with HCV genotype 2 and who achieved an RVR. However, as well as the report by Mangia *et al.* (6), retreatment of relapsers with the standard 24-week regimen yielded a high SVR rate comparable to that in patients treated initially with the standard 24-week regimen. Reduced durations of therapy may, therefore, be reasonable in patients who experience adverse events and are unlikely to tolerate 24 weeks of therapy as initial treatment. Currently, in patients with HCV genotype 2 and 3 infection and with RVR, a 12-week treatment regimen remains the shortest duration proven to maintain an acceptable rate of relapse as a short course of antiviral combination therapy with peginterferon and ribavirin (6). Further studies will be necessary to investigate the appropriate treatment duration with a sufficient SVR rate and with less adverse effect and less medical expense.

Table 3. Characteristics and outcomes of patients receiving the 8-week regimen

| Patient | Age (years) | Gender | Liver histology | HCV genotype | HCV RNA* concentration | HCV RNA at 2 weeks | Result | Time to relapse after the end of treatment (weeks) | Retreatment | Time to retreatment after the end of treatment (months) | HCV RNA† concentration | Result |
|---------|-------------|--------|-----------------|--------------|------------------------|--------------------|---------|--|--------------|---|------------------------|---------|
| 1 | 65 | M | A1/F1 | 2a | 4400 | Positive | Relapse | 4 | Yes | 2 | 1900 | SVR |
| 2 | 64 | F | Not done | 2b | 2500 | Positive | Relapse | 4 | Yes | 1 | 2100 | Replace |
| 3 | 29 | F | A1/F1 | 2b | 660 | Negative | SVR | | | | | |
| 4 | 65 | M | A2/F1 | 2b | 120 | Positive | SVR | | | | | |
| 5 | 28 | M | A1/F1 | 2a | 1800 | Positive | SVR | | | | | |
| 6 | 63 | F | A2/F2 | 2a | 1300 | Positive | Relapse | 4 | Yes | 2 | 590 | SVR |
| 7 | 59 | F | A2/F2 | 2a | 160 | Positive | Relapse | 4 | No (refused) | | | |
| 8 | 53 | M | A2/F2 | 2a | 1100 | Positive | SVR | | | | | |
| 9 | 46 | F | A1/F1 | 2a | 1000 | Positive | Relapse | 4 | Yes | 2 | 1300 | SVR |
| 10 | 58 | F | A1/F1 | 2a | 2100 | Positive | Relapse | 4 | Yes | 1.5 | 1400 | SVR |
| 11 | 66 | F | A1/F1 | 2a | 110 | Negative | SVR | | | | | |
| 12 | 68 | F | A1/F1 | 2a | 1400 | Positive | Relapse | 4 | Yes | 1.5 | 1700 | Replace |
| 13 | 21 | F | A1/F1 | 2a | 110 | Negative | Relapse | 8 | Yes | 6 | 70 | SVR |
| 14 | 68 | M | A1/F1 | 2a | 1000 | Positive | Relapse | 4 | Yes | 1 | 1200 | SVR |
| 15 | 51 | F | A1/F1 | 2b | 550 | Negative | Relapse | 4 | Yes | 3 | 2200 | SVR |

*Before initial treatment ($\times 10^3$ IU/ml).

†Before retreatment ($\times 10^3$ IU/ml).

No patient required reduction of peginterferon or ribavirin during the initial treatment.

Patient 6 required reduction of the peginterferon dose, and patients 4 and 15 required reduction of the ribavirin during retreatment.

No patient required discontinuation of peginterferon or ribavirin during initial treatment or retreatment.

HCV, hepatitis C virus; SVR, sustained virological response.

References

1. Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. *Hepatology* 2004; **39**: 1147–71.
2. Hadziyannis SJ, Sette H Jr, Morgan TR, *et al.* Peginterferon- α 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 2004; **140**: 346–55.
3. Manns MP, McHutchison JG, Gordon SC, *et al.* Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001; **358**: 958–65.
4. Zeuzem S, Hultcrantz R, Bourliere M, *et al.* Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients with HCV genotypes 2 or 3. *J Hepatol* 2004; **40**: 993–9.
5. Dalgard O, Bjoro K, Hellum KB, *et al.* Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. *Hepatology* 2004; **40**: 1260–5.
6. Mangia A, Santoro R, Minerva N, *et al.* Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. *N Engl J Med* 2005; **352**: 2609–17.
7. von Wagner M, Huber M, Berg T, *et al.* Peginterferon- α -2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. *Gastroenterology* 2005; **129**: 522–7.
8. Yu M-L, Dai C-Y, Huang J-F, *et al.* A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. *Gut* 2007; **56**: 553–9.
9. Shiffman ML, Suter F, Bacon BR, *et al.* Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. *N Engl J Med* 2007; **357**: 124–34.
10. McHutchison JG, Manns M, Patel K, *et al.* Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. *Gastroenterology* 2002; **123**: 1061–9.
11. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. *Hepatology* 1994; **20**: 15–20.
12. Fried MW, Shiffman ML, Reddy KR, *et al.* Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; **347**: 975–82.

Long-Term Follow-Up of Patients With Hepatitis C With a Normal Alanine Aminotransferase

Takashi Kumada,* Hidenori Toyoda, Seiki Kiriya, Yasuhiro Sone, Makoto Tanikawa, Yasuhiro Hisanaga, Akira Kanamori, Hiroyuki Atsumi, Makiko Takagi, Satoshi Nakano, Takahiro Arakawa, and Masashi Fujimori

Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Gifu, Japan

An attempt was made to identify factors influencing the cumulative probability of an increased alanine aminotransferase (ALT) level and hepatocarcinogenesis in hepatitis C patients with a normal ALT level initially. A total of 398 consecutive patients with a normal ALT level initially for 6 months or more and follow-up period longer than 3 years during the period January 1995 to December 2004 were included. Patients were classified by ALT level into three groups: Group A (3–20 IU/L), Group B (21–30 IU/L), and Group C (31–35 IU/L). Factors associated with the cumulative probability of increased ALT level and hepatocarcinogenesis were evaluated. Women in groups B and C and men in Group C showed high cumulative probabilities of increased ALT levels. Factors associated with increased ALT were a high ALT level (Group B, relative risk; 1.758 [95% confidence interval: 1.290–2.392], $P < 0.001$, Group C, 3.328 [2.256–4.909], $P < 0.001$), high lactate dehydrogenase level (2.352 [1.445–3.829], $P = 0.001$), or low total cholesterol level (1.957 [1.330–2.882], $P = 0.001$). Factors associated with incidence of hepatocellular carcinoma were increased age (3.088 [1.025–9.308], $P = 0.045$), high ALT level (Group C, 5.803 [1.530–22.066], $P = 0.010$), and high total bilirubin level (8.309 [2.235–30.888], $P = 0.002$). In patients with hepatitis C with a normal ALT level initially, an ALT level of 21–35 IU/L is a risk factor for an increased ALT level and hepatocarcinogenesis. *J. Med. Virol.* 81:446–451, 2009. © 2009 Wiley-Liss, Inc.

KEY WORDS: chronic hepatitis C; hepatitis C virus; normal alanine aminotransferase; hepatocarcinogenesis; long-term follow-up

INTRODUCTION

Hepatitis C virus (HCV) results in numerous complications including chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Disease progression and

clinical manifestations are heterogeneous, and the underlying mechanisms are not understood fully [Alberti et al., 1999; Marcellin, 1999; Alberti, 2005]. Approximately 30% of patients with chronic HCV infection show persistently normal alanine aminotransferase (ALT) levels, but the majority of these patients have some degree of histologic liver damage, which is usually mild [Marcellin et al., 1997; Tassopoulos, 1999; Bacon, 2002].

ALT activity is the laboratory marker that is used most extensively for the evaluation of liver disease [Craxi and Almasio, 1996; Pratt and Kaplan, 2000]. However, particularly in the case of chronic hepatitis C, ALT measurement often fails to identify patients with minimal to mild necroinflammatory activity [Zanella et al., 1995; Prati et al., 1996; Puoti et al., 1997]. Thus, determination of the true normal range of ALT activity is important for screening of large populations and for the recognition of occult liver abnormalities.

Recently, combination therapy with pegylated interferon and ribavirin has produced sustained virologic response rates of 53–63% in patients with chronic hepatitis C infection and an increased ALT level [Manns et al., 2001; Fried et al., 2002; Hadziyannis et al., 2004]. Zeuzem et al. [2004] reported that pegylated interferon plus ribavirin combination therapy was safe and effective in patients with persistently normal ALT levels.

Many studies have provided evidence that, although the majority of HCV carriers with a normal ALT level have minimal hepatic changes, a subgroup may have active and progressive liver disease that is difficult to predict based on clinical or biochemical parameters [Puoti, 2003; Alberti et al., 2004]. The association

*Correspondence to: Takashi Kumada, 4-86, Minaminokawa-cho, Ogaki, Gifu 503-8052, Japan.
E-mail: tkumada@he.mirai.ne.jp

Accepted 20 August 2008

DOI 10.1002/jmv.21342

Published online in Wiley InterScience
(www.interscience.wiley.com)

between ALT level and prognosis is not established clearly in HCV carriers with normal ALT levels. The aim of this retrospective study was to identify factors influencing the cumulative probability of an increased ALT level and hepatocarcinogenesis in patients with a normal ALT level initially.

MATERIALS AND METHODS

Patients

Five thousand three hundred consecutive patients positive for anti-HCV antibody visited the Department of Gastroenterology of Ogaki Municipal Hospital during the period from January 1995 to December 2004. The long-term prognosis of patients with a normal ALT level initially was evaluated in these cases. Normal ALT was defined at our institution as 3–35 IU/L. All patients included in this study fulfilled the following criteria: (1) positive for anti-HCV by a second- or third-generation enzyme-linked immunosorbent assay, (2) no evidence of hepatitis B virus infection, (3) exclusion of other causes of chronic liver disease (alcohol, hepatotoxic drugs, autoimmune hepatitis, primary biliary cirrhosis, hemochromatosis, or Wilson's disease), (4) detectable HCV-RNA and normal ALT level for longer than 6 months, (5) follow-up period longer than 3 years, (6) no evidence of hepatocellular carcinoma for at least 3 years from the start of the follow-up period, (7) no interferon treatment, and (8) measurement of ALT more than twice in 1 year. A total of 398 consecutive patients fulfilled these criteria.

All patients were followed-up at least every 6 months. During each follow-up examination, platelets, ALT, aspartate aminotransferase (AST), gamma glutamyl transpeptidase (gamma-GTP), prothrombin time (PT), total bilirubin, cholinesterase, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), total protein,

albumin, and total cholesterol were measured. The patients were classified into the following three groups according to initial ALT values: Group A (3–20 IU/L), Group B (21–30 IU/L), and Group C (31–35 IU/L). In some cases, the HCV genotype was determined and quantitation of HCV-RNA (Amplicor 2, Roche Diagnostics K.K., Tokyo, Japan) was undertaken. To detect early-stage hepatocellular carcinoma, ultrasonography (US), computed tomography (CT), and measurement of tumor markers (alpha-fetoprotein [AFP], *Lens culinaris* agglutinin-reactive AFP, des- γ -carboxyprothrombin) were carried out in all patients at least every 6 months. The median follow-up period was 8.8 years (range: 3.0–14.7 years). The total number of blood examinations was 21,259, and the median number was 23 (range: 6–241).

Statistical Analysis

Statistical analysis was performed with the Statistical Program for Social Science (SPSS 11.5 for Windows, SPSS Japan, Inc., Tokyo, Japan). Continuous variables are expressed as median (range). The Kruskal-Wallis test was used to assess continuous variables with a skewed distribution, and the chi-square test was used to assess categorical variables. Actuarial analyses of cumulative increased ALT levels and hepatocarcinogenesis were performed by the Kaplan-Meier method, and differences were tested with the log-rank test. Bonferroni correction was performed for multiple comparisons. The Cox proportional hazard model and forward selection method were used for univariate and multivariate analyses. Statistical significance was defined as $P < 0.05$.

RESULTS

Baseline patient characteristics are listed in Table I for the three groups. Viral concentration, AST, total

TABLE I. Patient Characteristics^a

| | Group A (n=180) | Group B (n=165) | Group C (n=53) | p |
|---|--------------------|--------------------|-------------------|---------|
| Age (years) | 61 (15–89) | 60 (11–93) | 58 (23–79) | NS |
| Sex (women/men) | 109/71 | 93/72 | 21/32 | 0.0265 |
| Genotype (type 1/type 2) | 30/28 | 57/32 | 19/12 | NS |
| Viral concentration (KIU/ml) | 440 (0.5–3,500) | 570 (0.5–7,700) | 960 (9.1–4,800) | 0.0082 |
| Measurement frequency of ALT | 17 (6–118) | 25 (6–241) | 27 (6–101) | <0.0001 |
| AST (IU/L) | 20 (10–60) | 26 (15–58) | 32 (15–121) | <0.0001 |
| Platelets (10 ⁴ /mm ³) | 19.9 (5.8–58.8) | 18.5 (4.5–31.8) | 16.9 (4.9–32.5) | 0.0018 |
| PT (%) | 100 (26–140) | 99 (22–145) | 102 (58–125) | NS |
| Gamma-GTP (IU/L) | 18 (6–175) | 22 (6–174) | 29 (12–475) | NS |
| Total bilirubin (mg/dl) | 0.4 (0.2–2.1) | 0.5 (0.2–2.7) | 0.5 (0.3–2.0) | 0.0027 |
| Cholinesterase (IU/L) | 276 (34–622) | 280 (65–710) | 279 (34–710) | NS |
| ALP (IU/L) | 230 (84–3458) | 246 (110–768) | 220 (84–659) | 0.0091 |
| LDH (IU/L) | 174 (92–567) | 182 (106–763) | 183 (107–360) | 0.0300 |
| Total protein (g/dl) | 7.1 (4.5–8.0) | 7.2 (5.6–9.0) | 7.4 (5.3–8.4) | 0.0037 |
| Albumin (g/dl) | 4.1 (2.0–4.8) | 4.2 (2.6–4.9) | 4.2 (2.8–4.7) | NS |
| Total cholesterol (mg/dl) | 177 (66–289) | 174 (72–301) | 164 (66–301) | NS |

ALT, alanine aminotransferase; Group A (ALT, 3–20 IU/L), Group B (ALT, 21–30 IU/L), Group C (ALT, 31–35 IU/L); AST, aspartate aminotransferase; PT, prothrombin time; Gamma-GTP, gamma glutamyl transpeptidase; ALP, alkaline phosphatase; LDH, lactate dehydrogenase.

^aContinuous variables are quoted as median (range).

bilirubin, LDH, and total protein were significantly higher in Groups B and C compared to Group A. Platelets were significantly lower in Groups B and C compared to Group A. ALP was significantly higher in Group B compared to Groups A and C.

Incidence of Increased ALT Level

Factors associated with an increased ALT level are listed in Table II. Male sex (risk ratio: 1.389 [95% confidence interval: 1.062–1.817], $P = 0.016$), high ALT level (Group B, 1.732 [1.297–2.346], $P < 0.001$; Group C, 3.400 [2.318–4.896], $P < 0.001$), high AST level (1.675

TABLE II. Factors Associated With an Increased ALT Level (Univariate Analyses)

| | Relative risk (95% CI) | <i>P</i> |
|--|------------------------|----------|
| Age | | |
| <60 years | 1 | 0.879 |
| >60 years | 0.979 (0.748–1.282) | |
| Sex | | |
| Women | 1 | 0.016 |
| Men | 1.389 (1.062–1.817) | |
| Genotype | | |
| Type 1 | 1 | 0.783 |
| Type 2 | 1.054 (0.726–1.529) | |
| Viral concentration | | |
| ≤100 KIU/ml | 1 | 0.783 |
| >100 KIU/ml | 1.030 (0.678–1.523) | |
| ALT | | |
| <20 IU/L | 1 | <0.001 |
| 21–30 IU/L | 1.732 (1.297–2.346) | <0.001 |
| 31–35 IU/L | 3.400 (2.318–4.986) | <0.001 |
| AST | | |
| ≤40 IU/L | 1 | 0.042 |
| >40 IU/L | 1.675 (1.020–2.750) | |
| Platelets | | |
| ≥12.0 × 10 ⁴ /mm ³ | 1 | 0.113 |
| <12.0 × 10 ⁴ /mm ³ | 1.030 (0.678–1.523) | |
| PT | | |
| <70% | 1 | 0.958 |
| ≥70% | 0.984 (0.546–1.774) | |
| Gamma-GTP | | |
| ≤56 IU/L | 1 | 0.667 |
| >56 IU/L | 0.894 (0.537–1.489) | |
| Total bilirubin | | |
| ≤1.2 mg/dl | 1 | 0.005 |
| >1.2 mg/dl | 2.257 (1.287–3.961) | |
| Cholinesterase | | |
| ≤431 IU/L | 1 | 0.099 |
| >431 IU/L | 0.723 (0.491–1.063) | |
| LDH | | |
| ≤250 IU/L | 1 | 0.002 |
| >250 IU/L | 2.151 (1.340–3.452) | |
| Total protein | | |
| ≥6.5 g/dl | 1 | 0.644 |
| <6.5 g/dl | 1.136 (0.661–1.955) | |
| Albumin | | |
| ≥3.5 g/dl | 1 | 0.022 |
| <3.5 g/dl | 1.712 (1.621–2.717) | |
| Total cholesterol | | |
| ≥130 mg/dl | 1 | <0.001 |
| <130 mg/dl | 2.217 (1.513–3.247) | |

CI, confidence interval; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; Gamma-GTP, gamma glutamyl transpeptidase; ALP, alkaline phosphatase; LDH, lactate dehydrogenase.




Fig. 1. Incidence of increased ALT for different initial ALT levels. Patients were classified into three groups according to ALT level: Group A (3–20 IU/L), Group B (21–30 IU/L), and Group C (31–35 IU/L). ALT increases at greater rates in Groups B and C compared to the increase in Group A and occurred at a greater rate in Group C compared to that in Group B ($P < 0.001$).

[1.020–2.750], $P = 0.042$), high total bilirubin level (2.257 [1.287–3.961], $P = 0.005$), high LDH level (2.151 [1.340–3.452], $P = 0.002$), low albumin level (1.712 [1.621–2.717], $P = 0.022$), and low total cholesterol level (2.217 [1.513–3.247], $P < 0.001$) were significantly associated with increased ALT by univariate analysis. The 3-, 5-, and 10-year cumulative incidences of increased ALT were 22.9%, 33.2%, and 48.1%, respectively, in Group A, 37.6%, 50.4%, and 70.3% in Group B, and 69.4%, 73.6%, and 82.9% in Group C. Increased ALT occurred at higher rates in Groups B and C than in Group A and occurred at a higher rate in Group C than in Group B ($P < 0.001$, Fig. 1). Among women, there was a significant difference between Group A and Groups B and C in the cumulative incidence of increased ALT ($P = 0.021$, $P = 0.036$, respectively, Fig. 2), but there was no significant difference between Group B and Group C. In contrast, among men, there were significant differences in the cumulative incidence of increased ALT between Groups A and B and Group C ($P < 0.001$, Fig. 3), but there was no significant difference between Group A and Group B.

Factors associated with increased ALT analyzed by the Cox proportional hazard model and the forward selection method are listed in Table III. High ALT level (Group B, 1.758 [1.290–2.392], $P < 0.001$; Group C, 3.328 [2.256–4.909], $P < 0.001$), high LDH level (2.352 [1.445–3.829], $P = 0.001$), and low total cholesterol level (1.957 [1.330–2.882], $P = 0.001$) were factors associated significantly with an increased ALT level.

Incidence of Hepatocellular Carcinoma

Hepatocellular carcinoma occurred in 16 of 398 patients (4%) in this follow-up study. The 3-, 5-, and 10-year cumulative incidences of hepatocellular carcinoma were none, none, and 4%, respectively, in Group A, none, 1.3%, and 4.3% in Group B, and none, 7.8%, and




Fig. 2. Relation between sex and incidence of increased ALT. In women (left), the cumulative incidence of increased ALT was significantly different between Group A and Groups B and C ($P = 0.021$, $P = 0.036$) but not between Group B and Group C. In men (right), the cumulative incidence of increased ALT differed significantly between Groups A and B and Group C ($P < 0.001$) but not between Group A and Group B.

14.4% in Group C. The cumulative incidence of hepatocellular carcinoma differed significantly between Group A and Group C ($P = 0.017$, Fig. 3) but not between Group A and Group B, or between Group B and Group C. Factors associated with the incidence of hepatocellular carcinoma analyzed by Cox proportional hazards modeling and the forward selection method are listed Table IV. Increased age (3.088 [1.025–9.308], $P = 0.045$), a high ALT level (Group C, 5.803 [1.530–22.066], $P = 0.010$), and high total bilirubin level (8.309 [2.235–30.888], $P = 0.002$) were factors associated significantly with the incidence of hepatocellular carcinoma.




Fig. 3. Incidence of hepatic carcinogenesis in HCV carriers with a normal ALT level initially. The cumulative incidence of hepatic carcinogenesis differed significantly between Group A and Group C ($P = 0.017$) but not between Group A and Group B or between Group B and Group C.

DISCUSSION

Criteria for the subgroup of HCV patients with a persistently normal ALT level differ with respect to the most appropriate cut-off for defining ALT normality in patients infected chronically with HCV and the most appropriate time frame and algorithm for defining a persistently normal ALT level. The current upper limit for normal ALT in patients with HCV is approximately 40 IU/L (range: 30–50 IU/L) [Alberti et al., 1992; Zanella et al., 1995; Prati et al., 1996; Pratt and Kaplan, 2000]. Studies have suggested that the normal values currently used clinically may be low [Piton et al., 1998; Hayashi et al., 2000; Prati et al., 2002]. Prati et al. [2002] reported that the upper limit for normal ALT was 19 IU/L in women and 30 IU/L in men after excluding patients with undiagnosed HCV infection and those with behavioral risk for blood-borne disease. In this study,

TABLE III. Factors Associated With an Increased ALT Level (Multivariate Analysis)

| | Relative risk (95% CI) | P |
|-------------------|------------------------|--------|
| ALT | | |
| <20 IU/L | 1 | <0.001 |
| 21–30 IU/L | 1.758 (1.292–2.392) | <0.001 |
| 31–35 IU/L | 3.328 (2.256–4.909) | <0.001 |
| LDH | | |
| ≤250 IU/L | 1 | 0.001 |
| ≥250 IU/L | 2.352 (1.445–3.829) | |
| Total cholesterol | | |
| ≥130 mg/dl | 1 | 0.001 |
| <130 mg/dl | 1.957 (1.330–2.882) | |

CI, confidence interval; ALT, alanine aminotransferase; LDH, lactate dehydrogenase.

TABLE IV. Factors Associated With Hepatic Carcinogenesis (Multivariate Analysis)

| | Relative risk (95% CI) | P |
|-----------------|------------------------|-------|
| Age (years) | | |
| ≤60 | 1 | 0.045 |
| >60 | 3.088 (1.025–9.308) | |
| ALT | | |
| <20 IU/L | 1 | 0.017 |
| 21–30 IU/L | 1.515 (0.415–5.530) | 0.529 |
| 31–35 IU/L | 5.803 (1.530–22.066) | 0.010 |
| Total bilirubin | | |
| ≤1.2 mg/dl | 1 | 0.002 |
| >1.2 mg/dl | 8.309 (2.235–30.888) | |

CI, confidence interval; ALT, alanine aminotransferase.

there was a significant difference in the cumulative incidence of increased ALT between Group A (ALT 3–20 IU/L) and Groups B (21–30 IU/L) and C (31–35 IU/L) among women. In contrast, among men, there were significant differences between Groups A and B and Group C. This is an interesting and important finding, suggesting that the upper limit for a normal ALT level should be revised to 30 IU/L for male patients and 20 IU/L for female patients with HCV infection. These data are consistent with the healthy limits in women and men proposed by Prati et al. [2002].

A persistently normal ALT level in patients with chronic hepatitis C has been defined generally as consecutive measurements within the normal range during a 6-month period [Marcellin et al., 1997; EASL International Consensus Conference on Hepatitis C, 1999]. In this study, patients with a normal ALT level for at least 6 months were selected according to this definition.

The natural course of HCV infection in patients with a normal ALT level is not understood fully. HCV patients with an initially and persistently normal ALT level may show disease progression on long-term follow-up as a consequence of transient ALT flares or of persistent biochemical reactivation of their liver disease. The incidence of ALT flares and/or of durable reactivation reported in HCV patients with a normal ALT level initially is variable and ranges from 15% to 27.5%, mainly as a consequence of different inclusion criteria and follow-up periods [Ohmiya et al., 2000; Tsuji et al., 2001; Puoti et al., 2002; Okanou et al., 2005]. In the present study, the 3-, 5-, and 10-year cumulative incidences of increased ALT were 35.3%, 45.8%, and 62.5%, respectively. Thus, the longer the follow-up period, the more the incidence increased. Factors associated with increased incidence of increased ALT were gender, ALT, AST, total bilirubin, LDH, albumin, and total cholesterol level. Among these, the ALT level was associated most strongly with increased ALT. However, Puoti et al. [2002] reported that baseline ALT levels (<20 IU/L vs. >21 IU/L) did not correlate with the incidence of ALT flares. Further research is necessary to reconcile these data.

Hepatocellular carcinoma occurred in 16 of 398 patients (4%) in the present study. Factors associated with hepatic carcinogenesis were increased age, gender, platelets, ALT, ALP, total cholesterol, and albumin in patients with abnormal ALT level [Kumada et al., 2007]. Thus, it is important to maintain a normal or low ALT level to prevent hepatic carcinogenesis.

Recently, the results of the first large multinational trial of a pegylated interferon plus ribavirin combination regimen in patients with a persistently normal ALT level became available [Zeuzem et al., 2004]. A total of 491 patients were assigned at random to three groups: either 24 or 48 weeks of treatment with pegylated interferon alfa-2a plus 800 mg/day ribavirin, or no treatment for 72 weeks. The overall sustained response rates were 30% and 52% in patients treated for 24 and 48 weeks, respectively, and the treatment outcome was equal in patients with an increased ALT level initially [Manns et al., 2001; Fried et al., 2002]. Median ALT levels were decreased consistently from the baseline level in treatment responders, confirming that, in many HCV patients with a normal ALT level according to current cut-off limits, ALT levels were in fact abnormal, reflecting possible underlying liver disease, and were normalized following successful antiviral therapy to what might be considered a true healthy level.

In conclusion, Groups B and C of women with ALT levels of 21–35 IU/L (corresponding to Groups B and C), Group C of men with ALT levels of 31–35 IU/L (corresponding to Group C) should be treated, taking into consideration patient age, motivation, and the possibility of complications. Maintenance of a low ALT level may prevent hepatic carcinogenesis, even in patients with ALT levels in the normal range.

REFERENCES

- Alberti A. 2005. Towards more individualized management of hepatitis C virus patients with initially or persistently normal alanine aminotransferase levels. *J Hepatol* 42:266–274.
- Alberti A, Morsica G, Chemello L, Cavalletto D, Noventa F, Pontisso P, Ruol A. 1992. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. *Lancet* 340:697–698.
- Alberti A, Chemello L, Benvegna L. 1999. Natural history of hepatitis C. *J Hepatol* 31:S17–S24.
- Alberti A, Benvegna L, Boccato S, Ferrari A, Sebastiani G. 2004. Natural history of initially mild chronic hepatitis C. *Dig Liver Dis* 36:646–654.
- Bacon BR. 2002. Treatment of patients with hepatitis C and normal serum aminotransferase levels. *Hepatology* 36:S179–S184.
- Craxi A, Almasio P. 1996. Diagnostic approach to liver enzyme elevation. *J Hepatol* 25:S47–S51.
- EASL International Consensus Conference on Hepatitis C. 1999. Paris, 26–28, February 1999, Consensus Statement. European Association for the Study of the Liver. *J Hepatol* 30:956–961.
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncalves FL, Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 347:975–982.
- Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Jr., Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, PEGASYS International Study Group. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 140:346–355.

- Hayashi J, Furusyo N, Ariyama I, Sawayama Y, Etoh Y, Kashiwagi S. 2000. A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. *J Infect Dis* 181:1523–1527.
- Kumada T, Toyoda H, Kiriya S, Sone Y, Tanikawa M, Hisanaga Y, Kanamori A, Kondo J, Yamauchi T, Nakano S. 2007. Relation between incidence of hepatic carcinogenesis and integration value of alanine aminotransferase in patients with hepatitis C virus infection. *Gut* 56:738–739.
- Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. *Lancet* 358:958–965.
- Marcellin P. 1999. Hepatitis C: The clinical spectrum of the disease. *J Hepatol* 31:S9–S16.
- Marcellin P, Levy S, Erlinger S. 1997. Therapy of hepatitis C: Patients with normal aminotransferase levels. *Hepatology* 26:S133–S136.
- Ohmiya M, Hayashi J, Ueno K, Furusyo N, Sawayama Y, Kawakami Y, Kinukawa N, Kashiwagi S. 2000. Effectiveness of interferon treatment for patients with chronic hepatitis C virus infection and normal aminotransferase levels. *Dig Dis Sci* 45:1953–1958.
- Okanoue T, Makiyama A, Nakayama M, Sumida Y, Mitsuyoshi H, Nakajima T, Yasui K, Minami M, Itoh Y. 2005. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. *J Hepatol* 43:599–606.
- Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, Sansonetti N, Opolon P. 1998. Factors associated with serum alanine transaminase activity in healthy subjects: Consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. *Hepatology* 27:1213–1219.
- Prati D, Capelli C, Zanella A, Mozzi F, Bosoni P, Pappalettera M, Zanuso F, Vianello L, Locatelli E, de Fazio C, Ronchi G, del Ninno E, Colombo M, Sirchia G. 1996. Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection. *Gastroenterology* 110:178–183.
- Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G. 2002. Updated definitions of healthy ranges for serum alanine aminotransferase levels. *Ann Intern Med* 137:1–10.
- Pratt DS, Kaplan MM. 2000. Evaluation of abnormal liver-enzyme results in asymptomatic patients. *N Engl J Med* 342:1266–1271.
- Puoti C. 2003. HCV carriers with persistently normal aminotransferase levels: Normal does not always mean healthy. *J Hepatol* 38:529–532.
- Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, Aldegheri L, Resta S. 1997. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. *Hepatology* 26:1393–1398.
- Puoti C, Castellacci R, Montagnese F, Zaltron S, Stornaiuolo G, Bergami N, Bellis L, Precone DF, Corvisieri P, Puoti M, Minola E, Gaeta GB. 2002. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: The Italian prospective study of the asymptomatic C carriers (ISACC). *J Hepatol* 37:117–123.
- Tassopoulos NC. 1999. Treatment of patients with chronic hepatitis C and normal ALT levels. *J Hepatol* 31:S193–S196.
- Tsuji K, Yamasaki K, Yamanishi M, Kawakami M, Shirahama S. 2001. Risk of alanine aminotransferase flare-up among asymptomatic hepatitis C virus RNA carriers: A 10-year follow-up study. *J Gastroenterol Hepatol* 16:536–540.
- Zanella A, Conte D, Prati D, Mozzi F, Capelli C, Zanuso F, Fraquelli M, Bosoni P, Vianello L, Pappalettera M, Velio P, Montagnolo G, Bianchi PA, Sirchia G. 1995. Hepatitis C virus RNA and liver histology in blood donors reactive to a single antigen by second-generation recombinant immunoblot assay. *Hepatology* 21:913–917.
- Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, Shiffman M, Farci P, Gitlin N, O'Brien CB, Lamour F, Lardelli P. PEGASYS Study NR16071 Investigator Group. 2004. Peginterferon alfa-2a (40 kiloDaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. *Gastroenterology* 127:1724–1732.

Impact of a Unified CT Angiography System on Outcome of Patients with Hepatocellular Carcinoma

Hidenori Toyoda¹
Takashi Kumada
Yasuhiro Sone

OBJECTIVE. The purpose of our study was to evaluate the impact of a unified CT angiography (CTA) system for the management of patients with hepatocellular carcinoma (HCC).

SUBJECTS AND METHODS. A total of 1,312 patients with HCC who had been diagnosed and treated between 1990 and 2003 were studied. The clinical characteristics and survival rate were compared between patients who underwent pretreatment evaluation of tumor progression by a unified CTA system and those who underwent evaluation by a conventional angiography system. In addition, the survival rates for 438 patients who underwent transcatheter arterial chemoembolization (TACE) as initial treatment were compared between patients who were treated using a unified CTA system and those who were treated without the system.

RESULTS. Overall, the survival rate was higher in patients who underwent pretreatment examination using a unified CTA system than in those who underwent examination without it ($p < 0.0001$). The survival rate was higher when focusing on patients with HCC of stage I ($p = 0.0093$). In patients who underwent TACE as an initial treatment, the survival rate was higher in patients treated by TACE using a unified CTA system than in those without it ($p = 0.0023$).

CONCLUSION. The more accurate and detailed pretreatment evaluation of HCC progression using a unified CTA system contributed to the improvement of survival of patients with HCC. In addition, it contributed to the improved efficacy of TACE with an increased survival rate.

Keywords: hepatocellular carcinoma, survival, transcatheter arterial chemoembolization, tumor progression, unified CT angiography system

DOI:10.2214/AJR.08.1368

Received June 8, 2008; accepted after revision July 29, 2008.

¹All authors: Department of Gastroenterology, Ogaki Municipal Hospital, 4-86 Minaminokawa, Ogaki, Gifu 503-8502, Japan. Address correspondence to T. Kumada (tkumada@he.mirai.ne.jp).

AJR 2009; 192:766-774

0361-803X/09/1923-766

© American Roentgen Ray Society

Hepatocellular carcinoma (HCC) is one of the most common malignancies, especially in southern and eastern Asia. The incidence of HCC is also increasing in the United States [1, 2]. The prognosis of patients with HCC has improved because of improvements in the management of such patients, including increased early detection of HCC, development of novel treatment options and enhanced treatment techniques, and the accurate evaluation of tumor progression [3]. Detailed and accurate evaluation of the progression of HCC, including the determination of the size, number, and location of tumors at diagnosis and the accurate evaluation of treatment response, is an important factor in the management of patients with HCC and contributes to the overall improved outcome.

Examination of liver tumor with CT during angiography, that is, CT during arterial portography (CTAP) [4] and CT during hepatic arteriography (CTHA) [5], reportedly provides precise and detailed information, includ-

ing the size, number, and location of HCC in the entire liver and vascular invasion by HCC [6-8]. In addition, in patients who underwent transcatheter arterial chemoembolization (TACE) as a treatment for HCC, the confirmation of the feeding arteries toward the tumor using CT in addition to digital subtraction arteriography (DSA) will improve the accuracy of the selection of arteries that should be embolized. Also, combination of TACE with simultaneous evaluation of its results using CT will improve the treatment efficacy.

A unified CT angiography (CTA) system was developed in 1996 [9, 10] and has been used in several liver centers in Japan. This system integrates CT and angiography and allows immediate and repeated CT examination during angiography examinations or the TACE procedure. We have applied this system for all angiography examinations or the TACE procedure for HCC in our institution since July 1997. In the present study, we evaluated the usefulness of a unified CTA system for the management of patients with HCC.

CT Angiography System for HCC

Subjects and Methods

Patients and Angiography Examination

A total of 1,312 patients were diagnosed with an initial HCC (not a recurrence) and underwent treatment for HCC at our institution between 1990 and 2003. The background characteristics of the study patients are shown in Table 1 (348 women and 964 men; mean age, 65.5 ± 9.3 years). Patients were diagnosed with HCC on the basis of histologic examination of tumor tissue taken from resected or biopsy specimens in 401 cases (30.6%). In the remaining 911 patients, diagnosis was made on the basis of clinical criteria [11, 12]: a pertinent clinical background (association with liver cirrhosis or viral hepatitis) and typical imaging findings. Typical imaging features of HCC include a mosaic pattern with a halo on B-mode sonographic images, hypervascularity on angiographic images, and a high-density mass on arterial phase dynamic CT images with a low-density mass on portal phase dynamic CT images obtained with a helical or MDCT scanner. CTAP and CTHA were performed when typical findings for HCC were not obtained by means of dynamic CT or angiography before July 1997, at which time a unified CTA system was introduced in our institution. CTAP and CTHA were performed in all patients after July 1997, and T1- and T2-weighted imaging associated with superparamagnetic iron oxide-enhanced MRI was performed when typical findings for HCC were not obtained by means of CTAP and CTHA during this period. In cases without typical features on imaging studies, a biopsy was performed to confirm the diagnosis of HCC. Of the 1,312 patients, 294 (22.4%) underwent hepatectomy, 271 (20.7%) were treated by locoregional ablative therapy including ethanol injection, microwave thermocoagulation, or radiofrequency ablation; and 438 (33.4%) were treated using TACE.

All patients underwent angiography for the diagnosis of HCC before treatment, regardless of the treatment options applied and including patients who did not undergo treatment as a consequence. The size, number, and location of tumors and portal vein invasion by the tumor were evaluated at angiography through hepatic arteriography and arterial portography. Angiography was performed without a unified CTA system in 603 patients before July 1997. CTAP was performed only when necessary for the diagnosis of HCC, with transportation of the patient from angiography to CT during this period. After July 1997, angiography was performed using the unified CTA system in all 709 patients. CTAP and CTHA were performed for all patients during this period. Patients were followed up from 0.4 months to 100.8 months (median, 16.9 months) at our institution.

The study protocol was approved by the hospital ethics committee and was in compliance with the Helsinki Declaration. Written informed consent was obtained from all patients before the study for use of the clinical, laboratory, and outcome data.

A Unified CTA System

A unified CTA system was introduced in our institution in July 1997. The unified system of helical CT and angiography (Interventional-CT, Toshiba Medical Systems) [9, 10] consists of helical CT (X-Vision Real, Toshiba Medical Systems) and angiography units in which DSA equipment with a C-arm (Angiorex, BLA-800A, Toshiba Medical Systems) is arranged in a linear configuration to form a common couch, facilitating quick transportation of the patient from one unit to the other for CT, including CTAP and CTHA, without risking dislodgment of the catheter.

TACE

Individual decisions regarding treatment of HCC were determined by the treating physicians and according to each patient's wishes. Patients were assessed initially for eligibility for hepatectomy. Principally, patients with three or fewer HCC tumors were recommended to undergo hepatectomy when they had Child-Pugh class A liver function. Those who declined or were deemed not eligible for hepatectomy were considered for locoregional ablative therapy with percutaneous ethanol injection, percutaneous microwave thermocoagulation, or radiofrequency ablation. Locoregional ablative therapy was selected as a treatment in patients with three or fewer HCC tumors that were < 3 cm in maximum size. Patients who were not eligible for either hepatectomy or locoregional ablative therapy and had no extrahepatic spread or portal vein thrombosis were offered TACE. This treatment policy was constant throughout the study period. No patient underwent liver transplantation as a treatment for HCC.

As a result, a total of 438 patients underwent TACE as an initial primary treatment for HCC. TACE was performed immediately after angiography for the diagnosis of HCC or at the latest within 2 weeks after diagnosis. TACE was performed solely with an angiography apparatus in 219 patients before July 1997 and with a unified CTA system in the other 219 patients after July 1997.

Before TACE, a baseline angiography with arterial portography and hepatic arteriography was performed in all patients. Hepatic arteriography in the right anterior oblique position was performed if deemed necessary. On the basis of the baseline study findings, the feeding artery was determined. Subsequently, a 2.5- or 2.8-French, 135-cm-long microcatheter (Tracker-18 or Rene-

TABLE 1: Background Characteristics of Study Patients (n = 1,312)

| Parameter | Value |
|--|-----------------|
| Age (y) | 65.5 \pm 9.3 |
| Sex (%) | |
| M | 964 (73.5) |
| F | 348 (26.5) |
| Total bilirubin (mg/dl) | 1.3 \pm 1.9 |
| Albumin (g/dl) | 3.3 \pm 0.6 |
| Prothrombin time (%) | 81.9 \pm 18.6 |
| Child-Pugh classification | |
| A | 794 (60.5) |
| B | 402 (30.6) |
| C | 116 (8.9) |
| Maximum tumor size (cm) | |
| < 2 | 442 (33.7) |
| 2-5 | 469 (35.7) |
| > 5 | 401 (30.6) |
| Number of tumors | |
| Single | 643 (49.0) |
| Multiple | 669 (51.0) |
| Portal vein invasion | |
| Absent | 1,025 (78.1) |
| Present | 287 (21.9) |
| Tumor stage ^a | |
| I | 288 (21.9) |
| II | 421 (32.2) |
| III | 315 (24.0) |
| IV | 288 (21.9) |
| Initial treatment | |
| Surgery | 294 (22.4) |
| Locoregional ablative therapies ^b | 271 (20.6) |
| Transcatheter arterial chemoembolization | 438 (33.4) |
| Other | 97 (7.4) |
| None | 212 (16.2) |

Note—Data in parentheses are percentages.

^aTNM tumor stage according to the Liver Cancer Study Group of Japan.

^bLocoregional ablative therapies include percutaneous ethanol injection, percutaneous microwave thermocoagulation, and radiofrequency ablation.

gade, Boston Scientific) with a double angle-shaped 0.016-inch, 180-cm-long guidewire covered by hydrophilic polymer (Radifocus, Terumo) was advanced through a 5-French catheter into the peripheral portion of the feeding artery as close to the lesion as possible. If the predicted noncancerous hepatic portion to be embolized was large enough